Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Clin Infect Dis ; 62(10): 1197-1202, 2016 05 15.
Artigo em Inglês | MEDLINE | ID: mdl-27118828

RESUMO

Evidence-based guidelines for implementation and measurement of antibiotic stewardship interventions in inpatient populations including long-term care were prepared by a multidisciplinary expert panel of the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. The panel included clinicians and investigators representing internal medicine, emergency medicine, microbiology, critical care, surgery, epidemiology, pharmacy, and adult and pediatric infectious diseases specialties. These recommendations address the best approaches for antibiotic stewardship programs to influence the optimal use of antibiotics.


Assuntos
Anti-Infecciosos , Revisão de Uso de Medicamentos , Controle de Medicamentos e Entorpecentes , Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/uso terapêutico , Epidemiologia/organização & administração , Humanos , Infectologia/organização & administração , Estados Unidos
2.
Clin Infect Dis ; 62(10): e51-77, 2016 05 15.
Artigo em Inglês | MEDLINE | ID: mdl-27080992

RESUMO

Evidence-based guidelines for implementation and measurement of antibiotic stewardship interventions in inpatient populations including long-term care were prepared by a multidisciplinary expert panel of the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. The panel included clinicians and investigators representing internal medicine, emergency medicine, microbiology, critical care, surgery, epidemiology, pharmacy, and adult and pediatric infectious diseases specialties. These recommendations address the best approaches for antibiotic stewardship programs to influence the optimal use of antibiotics.


Assuntos
Anti-Infecciosos , Revisão de Uso de Medicamentos , Controle de Medicamentos e Entorpecentes , Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/uso terapêutico , Epidemiologia/organização & administração , Humanos , Infectologia/organização & administração , Avaliação de Programas e Projetos de Saúde , Estados Unidos
3.
Curr Opin Infect Dis ; 26(6): 538-44, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24126716

RESUMO

PURPOSE OF REVIEW: The increasing rate of ventilator-associated pneumonia (VAP) caused by multidrug-resistant pathogens warrants the development of new treatment strategies. Carefully engineered delivery systems are undergoing evaluation to test the hypothesis that aerosolized administration of antibiotics will provide high local concentrations and fast clearance, which in turn may improve efficacy and decrease the risk of microbial resistance. RECENT FINDINGS: Recent studies indicate that aerosolized delivery systems for specially formulated antibiotics yield high local concentrations with rapid clearance and low systemic exposure. Preliminary clinical studies reveal that aerosolized delivery of antibiotics is well tolerated and active, when combined with intravenous antibiotics. No single aerosolized antibiotic is likely to provide broad-spectrum activity against both Gram-negative and Gram-positive bacteria. SUMMARY: Large multicenter trials are needed to determine whether preliminary findings will translate to improved clinical activity and decreased microbial resistance in VAP patients, and to optimize the use of aerosolized antibiotics.


Assuntos
Antibacterianos/administração & dosagem , Pneumonia Associada à Ventilação Mecânica/tratamento farmacológico , Administração por Inalação , Aerossóis , Ensaios Clínicos como Assunto , Farmacorresistência Bacteriana , Humanos , Pneumonia Associada à Ventilação Mecânica/microbiologia
4.
Ann Pharmacother ; 47(7-8): 1084-7, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23800751

RESUMO

In this commentary, we present evidence that unethical authorship (eg, guest and ghost authoring) and other publication practices are not restricted to the pharmaceutical industry; they also occur in academia. Such practices are not an industry problem--they are a research problem. To enhance trust in industry-sponsored research, companies have made rapid and far-reaching changes to their publication guidelines, policies, and procedures. Professional medical writers have adopted, and continue to implement, these changes. Although evidence indicates that industry practices are improving, there is certainly more to do, both in industry and academia. We invite readers to join ongoing efforts to promote ethical publication practices.


Assuntos
Autoria , Pesquisa Biomédica/ética , Indústria Farmacêutica/ética , Revisão por Pares/ética , Editoração/ética , Humanos
7.
J Arthroplasty ; 26(8): 1501-7, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21507604

RESUMO

We quantified surgical site infections (SSIs) after preoperative screening/selective decolonization before elective total joint arthroplasty (TJA) with 2-year follow-up and 2 controls. Concurrent controls (n = 2284) were patients of surgeons not participating in screening/decolonization. Preintervention controls (n = 741) were patients of participating surgeons who underwent TJA the previous year. Staphylococcus aureus nasal carriers (321/1285 [25%]) used intranasal mupirocin and chlorhexidine baths as outpatients. Staphylococcal SSIs occurred in no intervention patients (0/321) and 19 concurrent controls. If all SSIs occurred in carriers and 25% of controls were carriers, staphylococcal SSI rate would have been 3.3% in controls (19/571; P = .001). Overall SSI rate decreased from 2.7% (20/741) in preintervention controls to 1.2% (17/1440) in intervention patients (P = .009). Preoperative screening/selective decolonization was associated with fewer SSIs after elective TJA.


Assuntos
Antibacterianos/uso terapêutico , Artroplastia de Quadril , Artroplastia do Joelho , Cuidados Pré-Operatórios/métodos , Infecções Estafilocócicas/diagnóstico , Infecções Estafilocócicas/tratamento farmacológico , Staphylococcus aureus/isolamento & purificação , Infecção da Ferida Cirúrgica/prevenção & controle , Administração Intranasal , Antibacterianos/administração & dosagem , Clorexidina/administração & dosagem , Clorexidina/uso terapêutico , Estudos de Coortes , Seguimentos , Articulação do Quadril/microbiologia , Articulação do Quadril/cirurgia , Humanos , Articulação do Joelho/microbiologia , Articulação do Joelho/cirurgia , Programas de Rastreamento , Mupirocina/administração & dosagem , Mupirocina/uso terapêutico , Prevalência , Estudos Prospectivos , Estudos Retrospectivos , Infecção da Ferida Cirúrgica/epidemiologia , Infecção da Ferida Cirúrgica/microbiologia
8.
Diagn Microbiol Infect Dis ; 59(2): 173-9, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17574788

RESUMO

Linezolid is an attractive alternative for orthopedic infections because of oral bioavailability and activity against methicillin-resistant staphylococci and vancomycin-resistant enterococci. To determine efficacy and safety, we prospectively monitored 51 consecutive adults who were not vancomycin candidates and who received linezolid for 53 Gram-positive orthopedic infections, usually chronic osteomyelitis (n = 25) or prosthetic joint infection (n = 23). Pathogens were usually Staphylococcus aureus (n = 27) or coagulase-negative staphylococci (n = 19); 38 were methicillin resistant. After remission, 17 infections required long-term suppression, usually because of retained hardware. Clinical and microbiologic failure occurred in only one patient. The most common adverse events were thrombocytopenia (n = 5) and anemia (n = 5), necessitating treatment discontinuation in 3 patients. One patient developed reversible optic and irreversible peripheral neuropathy after 24 months of linezolid. Linezolid, with surgery, may be a reasonable alternative for Gram-positive orthopedic infections. We recommend weekly hematologic monitoring, and, if therapy lasts >2 months, periodic ophthalmologic monitoring.


Assuntos
Anti-Infecciosos , Bactérias Gram-Positivas/efeitos dos fármacos , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Osteomielite/tratamento farmacológico , Infecções Relacionadas à Prótese/tratamento farmacológico , Acetamidas/efeitos adversos , Acetamidas/uso terapêutico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Anti-Infecciosos/efeitos adversos , Anti-Infecciosos/uso terapêutico , Doença Crônica , Feminino , Bactérias Gram-Positivas/classificação , Infecções por Bactérias Gram-Positivas/microbiologia , Humanos , Linezolida , Masculino , Pessoa de Meia-Idade , Ortopedia , Osteomielite/microbiologia , Oxazolidinonas/efeitos adversos , Oxazolidinonas/uso terapêutico , Estudos Prospectivos , Infecções Relacionadas à Prótese/microbiologia , Resultado do Tratamento
9.
Account Res ; 23(3): 178-194, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26325353

RESUMO

To meet ethical and scientific obligations, authors should submit timely, high-quality manuscripts. Authors, however, can encounter ethical (e.g., authorship designation) and practical (e.g., time and resource limitations) challenges during manuscript preparation. Could professional medical writers-not ghostwriters-help authors address these challenges? This essay summarizes evidence countering three myths that may have hindered authors from considering the use of professional medical writers. Authors with sufficient time, writing expertise, and reporting guideline knowledge may meet their obligations without writing assistance. Unfortunately, not all authors are in this position. Decisions about writing support should be based on evidence, not myths.

11.
Infect Control Hosp Epidemiol ; 33(3): 250-6, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22314062

RESUMO

OBJECTIVE: To evaluate the economic impact of ventilator-associated pneumonia (VAP) on length of stay and hospital costs. Design. Retrospective matched cohort study. SETTING: Premier database of hospitals in the United States. PATIENTS: Eligible patients were admitted to intensive care units (ICUs), received mechanical ventilation for ≥2 calendar-days, and were discharged between October 1, 2008, and December 31, 2009. METHODS: VAP was defined by International Classification of Diseases, Ninth Revision (ICD-9), code 997.31 and ventilation charges for ≥2 calendar-days. We matched patients with VAP to patients without VAP by propensity score on the basis of demographics, administrative data, and severity of illness. Cost was based on provider perspective and procedural cost accounting methods. RESULTS: Of 88,689 eligible patients, 2,238 (2.5%) had VAP; the incidence rate was 1.27 per 1,000 ventilation-days. In the matched cohort, patients with VAP ([Formula: see text]) had longer mean durations of mechanical ventilation (21.8 vs 10.3 days), ICU stay (20.5 vs 11.6 days), and hospitalization (32.6 vs 19.5 days; all [Formula: see text]) than patients without VAP ([Formula: see text]). Mean hospitalization costs were $99,598 for patients with VAP and $59,770 for patients without VAP ([Formula: see text]), resulting in an absolute difference of $39,828. Patients with VAP had a lower in-hospital mortality rate than patients without VAP (482/2,144 [22.5%] vs 630/2,144 [29.4%]; [Formula: see text]). CONCLUSIONS: Our findings suggest that VAP continues to occur as defined by the new specific ICD-9 code and is associated with a statistically significant resource utilization burden, which underscores the need for cost-effective interventions to minimize the occurrence of this complication.


Assuntos
Infecção Hospitalar/economia , Infecção Hospitalar/epidemiologia , Contaminação de Equipamentos/economia , Custos de Cuidados de Saúde/estatística & dados numéricos , Pneumonia Associada à Ventilação Mecânica/economia , Pneumonia Associada à Ventilação Mecânica/epidemiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Análise de Variância , Estudos de Coortes , Infecção Hospitalar/etiologia , Bases de Dados Factuais , Feminino , Hospitais , Humanos , Unidades de Terapia Intensiva , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Estados Unidos/epidemiologia , Adulto Jovem
15.
Arch Immunol Ther Exp (Warsz) ; 58(4): 255-61, 2010 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20508997

RESUMO

Substantial confusion exists about the role of medical writers and editors (hereafter, medical communicators) in medical publication. Much of the confusion is due to the failure to recognize the difference between terms. Ghostwriting is unethical, whereas professional medical communication refers to legitimate writing and editing services provided by individuals who comply with ethical guidelines. The purpose of this article is to shed light on this subject by reviewing relevant guidelines and by providing practical tips for authors interested in collaborating with medical communicators. Specifically, this article addresses a series of questions, such as what to expect from medical communicators, how to evaluate them, and how to collaborate ethically and efficiently with them. To ensure that the process is ethical, authors should begin collaborating with the medical communicator early in the process, continue doing so throughout manuscript development, and control manuscript content. In addition, authors should disclose substantial contributions and funding sources of the medical communicator and all other individuals not meeting authorship criteria. To ensure that the process is efficient, authors should delegate time-consuming technical writing and editing tasks to the medical communicator.


Assuntos
Autoria , Jornalismo Médico , Editoração , Políticas Editoriais , Humanos , Jornalismo Médico/normas , Publicações Periódicas como Assunto , Editoração/ética , Editoração/normas
16.
Home Healthc Now ; 33(6): 346, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26034831

Assuntos
Autoria , Editoração
18.
Chest ; 135(4): 1087-1089, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19349404
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA